ResMed Inc.
RMDResMed Inc. is a healthcare company that specializes in developing, manufacturing, and marketing medical equipment primarily for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989, the company is known for its innovative sleep and respiratory care solutions, including devices such as CPAP machines, ventilators, and related accessories. ResMed operates globally, serving both individual patients and healthcare providers.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 18, 2026 | $0.60 | 2026-05-14 | 2026-05-14 |
| March 19, 2026 | $0.60 | 2026-02-12 | 2026-02-12 |
| December 18, 2025 | $0.60 | 2025-11-13 | 2025-11-13 |
| September 18, 2025 | $0.60 | 2025-08-14 | 2025-08-14 |
| June 12, 2025 | $0.53 | 2025-05-08 | 2025-05-08 |
Dividends Summary
- Consistent Payer: ResMed Inc. has rewarded shareholders with 56 dividend payments over the past 14 years.
- Total Returned Value: Investors who held RMD shares during this period received a total of $21.20 per share in dividend income.
- Latest Payout: The most recent dividend of $0.60/share was paid 30 days ago, on June 18, 2026.
- Yield & Schedule: RMD currently pays dividends quarterly with an annual yield of 1.21%.
- Dividend Growth: Since 2012, the dividend payout has grown by 252.9%, from $0.17 to $0.60.
- Dividend Reliability: RMD has maintained or increased its dividend for 56 consecutive payments.
Company News
ResMed has acquired Noctrix Health, a medical technology company specializing in wearable neuromodulation therapies for sleep and neurological conditions, for $340 million. This marks the first successful exit for Angelini Ventures, a corporate venture firm that invested in Noctrix during its $40 million Series C round in 2024. The acquisition wi...
Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains. With 84% of companies beating earnings expectations and 27% earnings growth, selective investing in fundamentally strong companies could outperform. The article highlights two healthcare stocks—DexCom and ResMed—as well-pos...
The global sleep apnea devices market is expected to grow at a CAGR of 7.05% from 2025 to 2034, driven by rising prevalence of sleep apnea affecting approximately 1 billion people worldwide, increased obesity rates, and technological innovations in CPAP, BiPAP, and oral appliances. Growth is further supported by expanding homecare and telemedicin...
The global respiratory care devices market is projected to grow from USD 24.3 billion in 2025 to USD 47.5 billion by 2034, at a CAGR of ~8%. Growth is driven by rising prevalence of chronic respiratory diseases (COPD, asthma, sleep apnea), increasing demand for home healthcare solutions, technological advancements, and post-COVID-19 awareness. No...
ResMed, a leader in CPAP machines and respiratory care devices, presents an attractive investment opportunity with 11% year-over-year revenue growth, expanding digital health capabilities across 140+ countries, and a forward P/E ratio of 22 (below its five-year average of 29). However, investors should be aware of potential headwinds including un...
